Faculty profile

Marc Carrier

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Ottawa

Marc Carrier

Associate Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
180 publications in the last five years, latest in 2026.
Senior (last) author on 51 recent papers, a sign of leading a research group.
Principal investigator on 11 research grants (11 CIHR), most recently in 2026.
Supervised 2 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

390

Publications

12,944

Citations

h-index

177

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Venous Thromboembolism Cancer Anticoagulants Bleeding Clonal Hematopoiesis Major Bleeding Critical Care / Intensive Care Unit (Icu)Venous Thromboembolism (Vte) Prophylaxis

Latest papers

Antithrombotic therapy at the end-of-life-continue or stop?
Research and practice in thrombosis and haemostasis · 2026
Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
HemaSphere · 2026 · senior author
Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial.
Thrombosis research · 2026 · senior author

All 390 publications

Latest funding

Clonal Hematopoiesis in Venous Thromboembolism: Advancing Precision in Risk Prediction and Treatment Outcomes
CIHR · 2026 · Principal investigator
$485,774
PROVE-ICU: Anti-Xa-guided, weight-based low-molecular-weight heparin thromboprophylaxis versus fixed dosing in critically ill adults - a multicentre pilot randomized trial
CIHR · 2026 · Principal investigator
$286,876
Role of Clonal Hematopoiesis in Ischemic Stroke following Pulmonary Embolism in Racialized Populations
CIHR · 2025 · Supervisor
$120,000

All 28 grants and awards

From the 150 most recent of 390 publications.

Antithrombotic therapy at the end-of-life-continue or stop?

Gurumurthy G, Kumar N, Reynolds L, Bassam B, Carrier M, Noble S, Khorana AA, Thachil J

Research and practice in thrombosis and haemostasis2026

DOI: 10.1016/j.rpth.2026.103459 PMID: 42027311

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?

Lauw MN, Middeldorp S, Carrier M

HemaSphere2026Senior author

DOI: 10.1002/hem3.70327 PMID: 41815440

Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial.

Saad M, Wang TF, Mallick R, Hill D, Lazo-Langner A, Tagalakis V, Wells PS, Carrier M

Thrombosis research2026Senior author

DOI: 10.1016/j.thromres.2026.109681 PMID: 41985366

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

Hamulyák EN, Wang TF, Kreuziger LB, Iyengar V, Carney BJ, Hoeben A, Özdemir BC, Cordova Serrano RD, Sanfilippo KM, Rozenblatt S, Beenen LFM, Yust-Katz S, Halperin E, Arad A, Lubetsky A, Carrier M, Massat B, Büller HR, Spectre G, Zwicker JI, Leader A, ABC Study Group

Blood vessels, thrombosis & hemostasis2026

DOI: 10.1016/j.bvth.2026.100140 PMID: 41852714

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Masurekar AN, Burkett KM, Rahgozar A, Walter RB, Othus M, Abrol K, Mortezaagha P, Thyagu S, Nampoothiri RV, Kennah M, Kekre N, Giguere P, Abduallah Y, Atkins H, Cieniak C, Berardi P, Ramsay T, Mallick R, Carrier M, Bredeson C, Allan D

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.12.996 PMID: 41482160

Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers.

Roy DC, Wang TF, Mallick R, Burger D, Carrier M, Wells P, Hawken S

European heart journal2026

DOI: 10.1093/eurheartj/ehaf1002 PMID: 41384379

Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.

Khan F, Tritschler T, Marx CE, Lanting V, Rochwerg B, Tran A, Fernando SM, Lorenzetti DL, Wunsch H, Holodinsky J, Fiest K, Stelfox HT, Delluc A, Fergusson DA, Le Gal G, Wells PS, Wang TF, Sanfilippo K, van Es N, Schrag D, Connors JM, Carrier M

European heart journal2026Senior author

DOI: 10.1093/eurheartj/ehaf453 PMID: 40579365

How I treat breakthrough thrombosis in patients with cancer.

Marx CE, Carrier M

Blood2026Senior author

DOI: 10.1182/blood.2025030790 PMID: 41557974

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.

Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C, Ravani P, Bossé D, Talarico R, Carrier M, Sood MM

Cancer2026

DOI: 10.1002/cncr.70266 PMID: 41797435

Primary thromboprophylaxis in patients with malignancy and central venous catheters: TRIM-Line randomized controlled trial - Design and rationale.

Wang TF, Ikesaka R, Mahé I, Hill D, Sperlich C, Tagalakis V, Shivakumar S, Leonard B, Cervi A, Kuruvilla P, Larose F, Matino D, Frosi Stella S, Séguin C, Al Raizah A, Le Gal G, Siegal DM, Delluc A, Mallick R, Lazo-Langner A, Wu C, Christopher D, Di Nisio M, Ageno W, Yazji B, Carrier M

Thrombosis and haemostasis2026Senior author

DOI: 10.1055/a-2963-4656 PMID: 42767263

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Marc Carrier

Research

Latest papers

Latest funding

Antithrombotic therapy at the end-of-life-continue or stop?

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?

Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial.

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers.

Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.

How I treat breakthrough thrombosis in patients with cancer.

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.

Primary thromboprophylaxis in patients with malignancy and central venous catheters: TRIM-Line randomized controlled trial - Design and rationale.

Frequent collaborators

Tzu-Fei Wang

Deborah Siegal

Sam Schulman

Grégoire Le Gal

Sudeep Shivakumar

James Demetrios Douketis

Mark Crowther

Peter Lawrence Gross

Yan Xu

Jeffrey Weitz

Alejandro Lazo-Langner

Ryan Zarychanski

Alexandre Tran

Vicky Tagalakis

Philip Wells

Marc Rodger

Deborah Siegal

Miriam Kimpton

Bram Rochwerg

Leslie Skeith

Dar Dowlatshahi

Shannon Bates

Srinivas Murthy

Doug Coyle

Ilias Cagiannos

Rick Ikesaka

Anand Kumar

Na Li

Rebecca Auer

Timothy Ramsay

Kwadwo Kyeremanteng

Joseph Shaw

Marc Carrier

Frederick Spencer

Carol Gonsalves

Dimitrios Scarvelis

Salmaan Kanji

Michael Fralick

Rinku Sutradhar

Sudeep Shivakumar